-
Researchers to reveal trial results for dual agonism in type 1 diabetes
Experts, including Klara Klein, MD, PhD, will discuss the possible benefits of a glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist (GLP-1/GIP RA) for people living with type 1 diabetes.
-
Symposium to analyze amylin as novel therapy for diabetes and weight loss
W. Timothy Garvey, MD, and other researchers will share new insights from trials, such as REDEFINE, exploring long-acting amylin analogs as mono-agonists and in combination with agonists for other hormone receptors.
-
Experts to review the benefits and challenges of GLP-1 RAs beyond diabetes and obesity
Investigators will give an overview of new therapies coming into the market. Panelist Donna Ryan, MD, will discuss clinical trials for incretin-based therapies.
-
Debate to focus on BMI and definitions of obesity
Body mass index (BMI) is one of the most controversial topics in the assessment of obesity today. Session Chair Robert Kushner, MD, previews a debate on whether this metric should be the primary tool in defining obesity.
-
Panel discussion to track diabetes across diverse populations in the U.S.
Jithin Sam Varghese, PhD, MTech, and other panelists will delve into the epidemiology of diabetes, social roadblocks, and variations in health outcomes across the country amid changing national demographics.
-
Experts to reveal results of retatrutide trials TRANSCEND-T2D-1 and TRIUMPH-1
Jonathan Campbell, PhD, and other panelists will share new data and address how this triple-hormone receptor agonist may unlock the next frontier of treatment for obesity and type 2 diabetes.
-
Primary results for SOLSTICE and VISTA to be shared for the first time
Vanita R. Aroda, MD, and Melanie Davies, CBE, MBChB, MD, FRCP, FRCGP, FMedSci, will review the latest data for a novel oral glucagon-like peptide-1 receptor agonist in people living with with type 2 diabetes or overweight or obesity.
-
Presenters to provide first look at data from REIMAGINE trials of cagrilintide/semaglutide for type 2 diabetes management
John B. Buse, MD, PhD, and other researchers will share study results and a broad understanding of amylin, from the hormone’s biology to potential translation to clinical care via phase 3 trials.
-
Experts to discuss AIDING results for automated insulin delivery in the hospital
Francisco Pasquel, MD, MPH, and other experts will share findings from this study evaluating automated insulin delivery initiated in the hospital compared with daily injections in people with type 1 or type 2 diabetes.
-
Symposium to highlight the latest chapters in the Standards of Care for Overweight and Obesity
The American Diabetes Association® (ADA) released the first chapters of this document in 2025. Kimberly Gudzune, MD, MPH, and other speakers will explain new standards on the screening and diagnosis of obesity, and on pharmacological treatments.